Phase 3 Readout
DSGN: Phase 3 Topline: Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
November 28, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- November 28, 2026
- Company
- Design Therapeutics, Inc. (DSGN)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
- Indication
- Type 2 Diabetes